Volume 8, Issue 4 (2023)
SJMR 2023, 8(4): 223-236 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jazayeri R. Comparison of the effects of CYP450 polymorphisms on the metabolism of efavirenz; a network meta-analysis study. SJMR 2023; 8 (4) : 1
URL: http://saremjrm.com/article-1-314-en.html
URL: http://saremjrm.com/article-1-314-en.html
Non-communiable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran. & Department of Genetics, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Abstract: (231 Views)
Pharmacogenetics plays a crucial role in personalized treatment. This field investigates how genetic variations influence drug responses, focusing on how genes affect the body's reaction to medications. This study explores the impact of genetic polymorphisms on the metabolism of efavirenz, a drug used in the treatment of HIV. The objective is to compare the effects of CYP450 polymorphisms on the metabolism of efavirenz using a network meta-analysis approach. This research, conducted following PRISMA guidelines, examines the pharmacogenetic effects on the efficacy and prevention of adverse drug reactions (ADRs) of efavirenz. The search strategy included a review of observational and interventional studies without language or publication date restrictions. Inclusion criteria involved studies assessing drug concentration, AUC, ADRs, and genotype comparisons. Two independent researchers selected studies and managed data. Data analysis was performed using STATA software, employing a combination of methods to assess heterogeneity and the overall impact of genetic polymorphisms. For continuous and binary outcomes, SMDs and ORs or HRs were used, respectively. Egger’s test was conducted to identify publication bias. In this systematic review and meta-analysis, a comprehensive assessment of the relationship between genetic variants and efavirenz metabolism was conducted. Out of 19,861 records, 96 studies were reviewed. These studies, from various countries, had sample sizes ranging from 20 to 6,045 participants. The results indicated that specific variants in genes such as CYP2B6 were significantly associated with changes in plasma efavirenz concentrations. These findings underscore the importance of genetic influences on drug metabolism in the treatment of HIV and the management of its side effects. This extensive systematic review and network meta-analysis evaluated the role of various genes in the metabolism of efavirenz and rivaroxaban. The analyses revealed that specific polymorphisms in the CYP2B6 gene significantly affect the plasma concentration of efavirenz, which is crucial for improving HIV treatment and reducing drug-related side effects. These findings highlight the significance of pharmacogenomic research and the consideration of genetic diversity in therapeutic management.
Article number: 1
Article Type: Systematical Review |
Subject:
Sterility Genetical Disorders
Received: 2023/12/23 | Accepted: 2024/01/20 | Published: 2024/08/31
Received: 2023/12/23 | Accepted: 2024/01/20 | Published: 2024/08/31
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
